Asia Pacific In Vitro Colorectal Cancer Screening Tests Market Report

Asia Pacific In Vitro Colorectal Cancer Screening Tests Market Size

The size of the Asia Pacific In vitro colorectal cancer screening tests market was valued at USD 0.38 billion in 2025. This market is expected to grow at a CAGR of 6.60% from 2026 to 2034 and be worth USD 0.68 billion by 2034 from USD 0.41 billion in 2026.

Colorectal cancer (CRC) is one of the most prevalent forms of cancer globally, with a rapidly escalating burden in the Asia Pacific region due to changing lifestyles, urbanization, and an aging population. In vitro colorectal cancer screening tests refer to diagnostic procedures conducted outside a living organism, typically on biological samples such as blood or stool, to detect early-stage CRC or precancerous lesions. These non-invasive or minimally invasive tests have gained traction as alternatives to traditional colonoscopy, especially in regions where healthcare access is uneven.

According to the World Health Organization’s International Agency for Research on Cancer (IARC), colorectal cancer ranked third in incidence and second in mortality among cancers in the Asia Pacific region in 2022. Countries like China, Japan, and South Korea report high prevalence rates, while emerging markets such as India and Indonesia are witnessing rapid increases in CRC cases. This rising disease burden has spurred demand for cost-effective, scalable screening solutions that can be deployed across diverse healthcare settings.

MARKET DRIVERS

Rising Incidence of Colorectal Cancer Across the Region

The increasing prevalence of colorectal cancer in the Asia Pacific region is a critical driver of the in vitro screening tests market. According to the National Cancer Center Japan, colorectal cancer has been the most commonly diagnosed cancer in Japan since 2015, with over 170,000 new cases reported annually. Similarly, in China, the Chinese National Cancer Center estimated that approximately 560,000 new CRC cases were diagnosed in 2023, marking a significant increase from previous years. Moreover, the aging population in several APAC countries exacerbates this trend. For instance, in South Korea, where more than 20% of the population is aged above 65, the risk of developing CRC increases significantly. As per Statistics Korea, individuals aged 60 and above accounted for nearly 70% of all CRC diagnoses in 2022.

Increasing Government Support and Healthcare Infrastructure Development

Government initiatives aimed at improving cancer screening coverage and healthcare infrastructure development are playing a pivotal role in expanding the Asia Pacific in vitro colorectal cancer screening tests market. Several governments in the region have introduced national cancer control programs and allocated funding to support early diagnosis and prevention strategies. In India, the Ministry of Health and Family Welfare launched the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) to strengthen early detection systems, including CRC screening. In addition, Japan has long-standing organized screening programs for colorectal cancer, which are partially funded by public health insurance. Infrastructure improvements, particularly in rural areas of countries like Indonesia and Vietnam, have also enabled broader access to diagnostic services.

MARKET RESTRAINTS

Low Awareness and Limited Public Participation in Screening Programs

The low awareness levels and limited public participation in screening programs remain significant restraints on market growth. Many populations, especially in rural and lower-income communities, lack sufficient knowledge about the importance of early cancer detection and available screening options. Similarly, in India, a survey conducted by the Indian Council of Medical Research revealed that only 18% of adults aged 50 and above had undergone any form of CRC screening.

This lack of awareness translates into poor screening uptake. In Thailand, for example, despite the availability of free fecal occult blood tests through the Universal Health Coverage Scheme, participation rates remained below 20% as of 2022, according to the Thai Ministry of Public Health. Cultural stigma associated with bowel-related diseases and reluctance to engage in medical testing also play a role in discouraging participation. Moreover, misinformation and misconceptions about cancer such as fatalistic beliefs or fear of diagnosis further hinder screening adoption.

High Cost of Advanced In Vitro Diagnostic Technologies

The high cost of advanced in vitro diagnostic technologies poses a significant barrier to widespread adoption of colorectal cancer screening tests in the Asia Pacific region. While newer molecular-based tests such as stool DNA tests (e.g., Cologuard) offer improved sensitivity and specificity compared to traditional fecal immunochemical tests (FIT), their relatively high price limits accessibility, especially in low- and middle-income countries. Even in high-income APAC countries such as Australia and Japan, reimbursement policies for advanced screening tests are often limited. According to Australia’s Department of Health, only FIT tests are fully subsidized under the National Bowel Cancer Screening Program, which is leaving newer technologies accessible primarily to those who can afford to pay out of pocket.

MARKET OPPORTUNITIES

Expansion of Telehealth and Digital Diagnostics Platforms

The rapid expansion of telehealth and digital diagnostics platforms presents a transformative opportunity for the Asia Pacific in vitro colorectal cancer screening tests market. In China, digital health companies such as WeDoctor and Ping An Good Doctor have integrated home-based colorectal cancer screening kits into their platforms, allowing users to order tests online and receive results via mobile apps. According to a 2023 report by the China Internet Network Information Center, over 600 million people in China accessed online healthcare services in 2022, indicating strong consumer adoption of digital health tools. Japan and South Korea are also leveraging AI-driven diagnostics to enhance screening accuracy. As per the Japan Medical Association, AI-assisted interpretation of stool test results has improved diagnostic efficiency by up to 25%, reducing the workload on pathologists and expediting patient follow-up.

Advancements in Biomarker Discovery and Non-Invasive Testing

Significant advancements in biomarker discovery and the development of non-invasive in vitro colorectal cancer screening tests are opening new avenues for market expansion in the Asia Pacific region. A key example is the Epi proColon test developed by Epigenomics AG, which detects SEPT9 gene methylation in blood plasma and has shown promising performance in clinical trials across multiple Asian populations. Additionally, companies such as Guardant Health and Freenome are investing heavily in liquid biopsy technologies that combine machine learning with multi-omics approaches to detect CRC at earlier stages.

MARKET CHALLENGES

Regulatory Heterogeneity Across Asia Pacific Markets

One of the foremost challenges facing the Asia Pacific in vitro colorectal cancer screening tests market is the regulatory heterogeneity across different countries. In China, the National Medical Products Administration (NMPA) mandates extensive local clinical trials before approving in vitro diagnostic (IVD) products, which can delay market entry by 12–18 months. Similarly, in India, the Central Drugs Standard Control Organization (CDSCO) has recently introduced stricter IVD regulations under the Medical Devices Rules, 2023, increasing compliance burdens for manufacturers. These fragmented regulatory landscapes not only increase time-to-market but also elevate compliance costs for global players seeking regional expansion. According to a 2023 report by Deloitte, multinational diagnostic firms spend up to 30% more on regulatory affairs in the Asia Pacific compared to other regions.

Limited Reimbursement and Insurance Coverage for Advanced Screening Tests

Limited reimbursement and inadequate insurance coverage for advanced in vitro colorectal cancer screening tests pose a persistent challenge to market growth in the Asia Pacific region. In Australia, while the government subsidizes fecal immunochemical tests (FIT) under the National Bowel Cancer Screening Program, advanced stool DNA tests remain uncovered unless prescribed under specific circumstances. According to the Australian Institute of Health and Welfare, only 15% of privately insured Australians had access to full reimbursement for non-standard CRC screening tests in 2022.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Test Type Insights

The fecal occult blood tests segment accounted in holding 55.4% of the Asia Pacific in vitro colorectal cancer screening tests market share in 2024. In Japan, FOBT remains the most utilized method under the National Cancer Screening Program, with more than 15 million kits distributed annually, as reported by the Japanese Ministry of Health, Labour and Welfare. Moreover, the low cost of FOBT, typically ranging from USD 5 to USD 15 per test, makes it an accessible option in price-sensitive markets such as India and Indonesia, where out-of-pocket healthcare expenditures are high.

The biomarker-based in vitro colorectal cancer screening tests segment is expected to witness a CAGR of 14.2% from 2025 to 2033. A key driver is the growing research focus on methylation markers and circulating tumor DNA (ctDNA) for early CRC detection. Additionally, companies such as Genomictree and BioCore are commercializing proprietary biomarker assays that offer improved specificity over traditional FOBT methods. Furthermore, regulatory support in countries like Singapore and Australia has accelerated the adoption of these tests. The Health Sciences Authority (HSA) of Singapore approved multiple ctDNA-based kits between 2021 and 2023, encouraging local diagnostics firms to scale production.

By End-use Insights

The hospitals and clinics segment was the largest and held 52.3% of the Asia Pacific in vitro colorectal cancer screening tests market share in 2024. In China, major tertiary hospitals such as Peking University Cancer Hospital conduct over 1 million CRC screenings annually, many of which involve fecal immunochemical or biomarker-based tests. Additionally, in Japan, hospitals serve as primary distribution centers for national screening programs. The Japanese Ministry of Health reports that over 12 million CRC screening tests were administered through hospital networks in 2022 alone, representing a consistent upward trend.

The diagnostic laboratories segment is expected to grow with an expected CAGR of 12.8% from 2025 to 2033. India exemplifies this trend, where companies like Thyrocare Technologies and Dr. Lal PathLabs have established extensive lab networks covering over 1,500 collection centers nationwide, as reported by the Indian Diagnostic Association in 2023. These labs now offer bundled CRC screening packages, including stool DNA tests, which can be ordered online and performed via doorstep sample pickup. In Australia, Sonic Healthcare and Primary Health Care Limited have expanded their gastrointestinal diagnostics offerings, incorporating advanced molecular screening tests that require specialized lab processing. According to Deloitte’s 2023 Australian Diagnostic Industry Outlook, the number of lab-based CRC tests conducted outside hospitals grew by nearly 35% between 2020 and 2023, indicating a shift toward decentralized testing ecosystems.

COUNTRY-LEVEL ANALYSIS

China In Vitro Colorectal Cancer Screening Tests Market Insights

China was the top performer in the Asia Pacific in vitro colorectal cancer screening tests market by holding 28.3% of the share in 2024. The Chinese government plays a central role in driving market growth through large-scale population screening initiatives. Under the Rural Cancer Early Detection Program, more than 60 million individuals received free FOBT kits between 2018 and 2023, as reported by the Chinese Center for Disease Control and Prevention. Private sector involvement is also accelerating innovation. Domestic biotech firms such as WuXi AppTec and BGI Genomics are developing localized versions of stool DNA tests, while partnerships with global players like Exact Sciences are expanding technology access.

Japan In Vitro Colorectal Cancer Screening Tests Market Insights

Japan was positioned second by holding 19.2% of the Asia Pacific in vitro colorectal cancer screening tests market share in 2024. The country benefits from one of the most structured national screening programs globally. Under Japan’s National Cancer Screening Program, individuals aged 40 and above receive annual fecal immunochemical test (FIT) kits via mail. In addition to government-led efforts, Japan's robust healthcare infrastructure supports the integration of advanced in vitro diagnostics. Companies like Sysmex Corporation and Fujirebio have developed highly sensitive FIT and biomarker assays tailored for domestic use.

South Korea In Vitro Colorectal Cancer Screening Tests Market Insights

South Korea's in vitro colorectal cancer screening tests market is lucratively to grow with a prominent growth opportunities in the coming years. According to the Korean Statistical Information Service, CRC was ranked as the second most common cancer in South Korea in 2023, with over 45,000 new cases reported annually. The National Cancer Screening Program includes CRC screening for individuals aged 50 and above, resulting in a participation rate of 52% in 2022, as per the National Cancer Center Korea. Technological advancement is a defining feature of South Korea’s market landscape. Companies such as SD Biosensor and Genomictree have pioneered point-of-care CRC screening solutions that combine portability with high sensitivity. Additionally, digital pathology platforms like Lunit INSIGHT are being used to improve FIT result analysis, enhancing early detection outcomes.

Australia In Vitro Colorectal Cancer Screening Tests Market Insights

Australia's in vitro colorectal cancer screening tests market is set to witness huge growth opportunities in the coming years. The country’s National Bowel Cancer Screening Program (NBCSP), managed by the Department of Health, has been instrumental in expanding test coverage. As of 2023, the NBCSP provides free biennial fecal immunochemical tests (FIT) to Australians aged 50–74, with over 4.5 million participants in the 2022–2023 cycle, according to the Australian Institute of Health and Welfare. Additionally, Australia is an early adopter of advanced biomarker-based tests. Private diagnostics firms such as Clinical Genome and Genetic Technologies have introduced methylated DNA assays that complement standard FIT usage.

India In Vitro Colorectal Cancer Screening Tests Market Insights

India is likely to have significant growth with the rising CRC incidence and expanding healthcare access. According to the Indian Council of Medical Research, colorectal cancer cases in India increased by over 25% between 2018 and 2023, with projections indicating a further 40% rise by 2030. Government initiatives such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) are facilitating early detection efforts. Simultaneously, private diagnostics chains like Metropolis Diagnostics and Dr. Lal PathLabs have introduced affordable stool DNA testing packages priced below USD 30, making advanced screening more accessible.

COMPETITIVE LANDSCAPE

The Asia Pacific in vitro colorectal cancer screening tests market is highly dynamic, characterized by a mix of global leaders and emerging regional players striving to capture a larger share of a rapidly growing sector. Competition is driven by technological differentiation, pricing strategies, and the ability to align with national healthcare programs. Established international firms leverage their expertise in molecular diagnostics and regulatory approvals to maintain an edge, while domestic companies capitalize on localized manufacturing, cost efficiency, and strong distribution networks. Innovation remains a central battleground, with many players focusing on developing more sensitive and user-friendly tests that can be easily integrated into public health systems. Additionally, there is a growing emphasis on digital health integration, where companies are embedding AI-assisted diagnostics and telemedicine compatibility into their offerings to enhance accessibility.

KEY MARKET PLAYERS

Some of the noteworthy companies in the Asia Pacific in vitro colorectal cancer screening tests market profiled in this report are

• Abbott
• Epigenomics AG
• Beckman Coulter, Inc.
• Eiken Chemical Co., Ltd.
• Sysmex Corporation
• Siemens Healthineers AG
• Quest Diagnostics Incorporated
• Oncocyte Corporation
• Merck KGaA
• Immunostics Inc.
• Kyowa Kirin Co., Ltd.
• Randox Laboratories Ltd.
• R-Biopharm AG

TOP LEADING PLAYERS IN THE MARKET

Exact Sciences is a global leader in cancer screening and diagnostics, best known for its Cologuard stool DNA test, which has set a benchmark in non-invasive colorectal cancer detection. While originally developed for the U.S. market, the company has expanded its influence in the Asia Pacific through strategic partnerships and technology licensing agreements. Its innovations have encouraged regional players to develop localized versions of advanced in vitro tests. The company's emphasis on biomarker research and regulatory compliance has made it a key reference point for diagnostic accuracy and reliability.

Epigenomics specializes in DNA methylation-based diagnostic solutions, with its flagship product, Epi proColon, being one of the first blood-based tests approved for colorectal cancer screening. The company has contributed significantly to the adoption of liquid biopsy approaches in early cancer detection across the Asia Pacific. Collaborations with local diagnostic firms and participation in clinical trials across China and South Korea have enhanced its regional footprint. Epigenomics' focus on improving sensitivity and accessibility has positioned it as a pioneer in next-generation CRC screening technologies.

Sysmex, a Japanese multinational diagnostics company, plays a dominant role in the Asia Pacific market due to its strong presence in hospital and laboratory networks. It offers a wide range of fecal immunochemical tests (FIT) and supports automated testing platforms that enhance efficiency and scalability. Sysmex's commitment to integrating AI into diagnostic workflows has improved result interpretation and turnaround times. Its deep-rooted relationships with healthcare providers and government agencies make it a critical player in driving widespread CRC screening initiatives across the region.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

One major strategy employed by leading companies is product innovation and development of advanced biomarker-based tests, aimed at enhancing detection accuracy and expanding screening options beyond traditional methods. High-sensitivity assays that cater to diverse patient preferences and clinical needs by investing heavily in R&D, firms are introducing non-invasive.

Another key approach is strategic collaborations and partnerships with local healthcare providers, research institutions, and governments by enabling faster market entry and better alignment with national screening programs. These alliances help companies tailor their offerings to regional requirements while building trust among end-users.

Companies are leveraging telehealth platforms, mobile apps, and home sample collection services to improve accessibility and convenience, thereby increasing screening uptake and reinforcing brand loyalty in competitive markets.

RECENT MARKET DEVELOPMENTS

• In January 2024, Exact Sciences entered into a collaboration with a leading Chinese diagnostics firm to co-develop localized versions of its stool DNA test, which is aiming to expand access to advanced screening tools in mainland China and neighboring countries.
• In March 2024, Epigenomics AG launched a new clinical trial initiative in South Korea to validate the performance of its SEPT9-based blood test in Asian populations by strengthening its position in the region’s liquid biopsy segment.
• In July 2024, Sysmex Corporation introduced an AI-powered interpretation module for fecal immunochemical test results, which is enhancing diagnostic speed and accuracy across hospital and lab settings in Japan and Southeast Asia.
• In October 2024, a prominent Indian diagnostics company partnered with a Singaporean biotech startup to offer affordable, home-based colorectal cancer screening kits, targeting urban and semi-urban populations with limited access to conventional screening.
• In December 2024, a joint venture between two Australian firms led to the launch of a cloud-connected platform for real-time analysis and reporting of in vitro CRC screening results by aiming to streamline workflow efficiencies in private diagnostic centers.

MARKET SEGMENTATION

This Asia Pacific In vitro colorectal cancer screening tests market research report is segmented and sub-segmented into the following categories.

By Test

• Fecal Occult Blood Tests
  • Guaiac FOB Stool Test
  • Immuno-FOB Agglutination Test
  • Lateral Flow Immuno-FOB Test
  • Immuno-FOB ELISA Test
• Biomarker Tests
• Other Methods

By End-use

• Hospitals and Clinics
• Diagnostic Laboratories
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest Of APAC